Curaleaf completes buyout of remaining stake in Germany's Four 20 Pharma

Curaleaf Holdings has completed the buyout of the remaining 45% stake not previously owned in Four 20 Pharma GmbH, a fully EU-GMP and GDP licensed German producer and distributor of medical cannabis. Four 20 Pharma is recognized for its high-quality cultivation, pharmaceutical-grade processing, and comprehensive distribution network across Germany and select European markets, serving nursing homes, pharmacies, and research institutions. The company's commitment to compliance, patient care, and scientific rigor positions it as a cornerstone of Europe's medical cannabis ecosystem.

The full acquisition of Four 20 Pharma strengthens Curaleaf's vertically integrated, global supply chain, from owned cultivation sources in Portugal and Canada through to licensed distribution across Germany, delivering a true seed-to-patient quality guarantee and full oversight at every stage. Since the initial agreement in 2022, Curaleaf and Four 20 Pharma have collaborated closely to expand patient access, advance research initiatives, and streamline the international medical cannabis supply chain, validating a data-driven approach to education, cultivation, and product development.

© Curaleaf

"Completing this buyout of the remaining stake in Four 20 Pharma reinforces our commitment to Europe and underscores the strategic importance of building high-quality, locally anchored operations in a market that will continue to grow exponentially," said Boris Jordan, CEO and Chairman of Curaleaf. "Four 20 Pharma's leadership in production, compliance, and distribution allows us to expand patient access to medical cannabis while driving innovation across the international market. This investment has been a meaningful, strategic anchor in our international strategy, and we're looking forward to continued long-term growth in Europe."

"Joining the Curaleaf family as a fully integrated subsidiary marks an exciting new chapter for Four 20 Pharma," said Torsten Greif, Founder and Managing Director of Four 20 Pharma. "We built this company on an uncompromising commitment to quality, compliance, and patient care, values that align perfectly with Curaleaf's international mission. Together, we are uniquely positioned to set the standard for medical cannabis across regulated markets worldwide."

Building on Four 20 Pharma's success in Germany, Curaleaf has already launched the Four 20 brand in the United Kingdom and Poland and intends to continue expanding the brand across additional international markets, leveraging the blueprint of quality and compliance that has made Four 20 Pharma one of Germany's most trusted medical cannabis brands.